Comparative Outcomes of Catheter-Directed Thrombolysis Plus Systemic Anticoagulation Versus Systemic Anticoagulation Alone in the Management of Intermediate-Risk Pulmonary Embolism in a Systematic Review and Meta-Analysis.

anticoagulation catheter-directed thrombolysis intermediate-risk pulmonary embolism meta-analysis submassive pulmonary embolism

Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 10 2023
Historique:
received: 14 06 2023
revised: 26 07 2023
accepted: 31 07 2023
medline: 22 9 2023
pubmed: 25 8 2023
entrez: 24 8 2023
Statut: ppublish

Résumé

There are limited and conflicting data on the initial management of intermediate-risk (or submassive) pulmonary embolism (PE). This study sought to compare the outcomes of catheter-directed thrombolysis (CDT) in combination with systemic anticoagulation (SA) to SA alone. A systematic search was conducted in MEDLINE, EMBASE, PubMed, and the Cochrane databases from inception to March 1, 2023 for studies comparing the outcomes of CDT + SA versus SA alone in intermediate-risk PE. The outcomes were in-hospital, 30-day, 90-day, and 1-year mortality; bleeding; blood transfusion; right ventricular recovery; and length of stay. Random-effects models was used to calculate the pooled incidence and risk ratios (RRs) with 95% confidence intervals (CIs). A total of 15 (2 randomized and 13 observational) studies with 10,549 (2,310 CDT + SA and 8,239 SA alone) patients were included. Compared with SA, CDT + SA was associated with significantly lower in-hospital mortality (RR 0.41, 95% CI 0.30 to 0.56, p <0.001), 30-day mortality (RR 0.34, 95% CI 0.18 to 0.67, p = 0.002), 90-day mortality (RR 0.34, 95% CI 0.17 to 0.67, p = 0.002), and 1-year mortality (RR 0.58, 95% CI 0.34 to 0.97, p = 0.04). There were no significant differences between the 2 cohorts in the rates of major bleeding (RR 1.39, 95% CI 0.72 to 2.68, p = 0.56), minor bleeding (RR 1.83, 95% CI 0.97 to 3.46, p = 0.06), and blood transfusion (RR 0.34, 95% CI 0.10 to 1.15, p = 0.08). In conclusion, CDT + SA is associated with significantly lower short-term and long-term all-cause mortality, without any differences in major/minor bleeding, in patients with intermediate-risk PE.

Identifiants

pubmed: 37619491
pii: S0002-9149(23)00739-7
doi: 10.1016/j.amjcard.2023.07.170
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Meta-Analysis Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

249-258

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflicts of interest to declare.

Auteurs

Akshay Machanahalli Balakrishna (AM)

Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska.

Ruth Ann Mathew Kalathil (RAM)

Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska.

Suma Pusapati (S)

Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska.

Auras Atreya (A)

Division of Cardiovascular Medicine, Department of Medicine, University of Arkansas School of Medicine, Little Rock, Arkansas.

Aryan Mehta (A)

Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut.

Mridul Bansal (M)

Department of Medicine, East Carolina Brody School of Medicine, Greenville, North Carolina.

Vikas Aggarwal (V)

Section of Cardiovascular Medicine, Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan.

Mir B Basir (MB)

Section of Cardiovascular Medicine, Department of Medicine, Henry Ford Hospital, Detroit, Michigan.

Ajar Kochar (A)

Section of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.

Alexander G Truesdell (AG)

Virginia Heart/Inova Heart and Vascular Institute, Falls Church, Virginia.

Saraschandra Vallabhajosyula (S)

Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina. Electronic address: svallabh@wakehealth.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH